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 CURRENTOPINION Organ protection in allograft recipients: anesthetic
strategies to reduce postoperative morbidity and
mortality
Fre´de´rique Hovaguimiana, Martin Schla¨pfera,b, and
Beatrice Beck-Schimmera,b
Purpose of review
Organ protection remains a primary objective in the anesthetic management of patients undergoing
transplantation. An ongoing effort has been made to develop strategies to improve graft outcome and
reduce postoperative morbidity and mortality, but trials have reported conflicting results. The aim of this
review was to provide a comprehensive summary of the anesthetic management in transplant recipients
and to identify current strategies for organ protection.
Recent findings
Decreasing blood products requirements, intraoperative blood glucose control and adequate postoperative
pain therapy may improve patient outcome. Vasopressors have been reported to reduce perioperative
bleeding but might be associated with postoperative acute renal failure in liver transplantation. Early
extubation may increase survival rates in recipients. These perioperative challenges, along with other
protective strategies, have been addressed in 20 recently published studies: 10 randomized controlled
trials, nine retrospective studies and one prospective study.
Summary
This review identified several promising strategies ensuring organ protection and improving patient
outcome after solid organ transplantation. However, as outcomes were difficult to compare, further
evidence will be needed before drawing firm conclusions.
Keywords
anesthesia, organ protection, postoperative complications, transplantation
INTRODUCTION
Over thepast twodecades, theperioperativemanage-
ment of patients undergoing solid organ transplan-
tation sustained major developments, leading to a
significant reduction in mortality and morbidity
rates. In their 2011 statement, the Organ Procure-
mentandTransplantationNetwork reported anover-
all increase in graft survival rates after kidney, heart,
lung and liver transplantation [1
&
–4
&
]. Although
1-year survival after liver transplantation was only
33% in 1985, this proportion has been recently
suggested to reach85%forpatients transplantedafter
2004 [5]. Similar improvement has been described in
1-year survival rates following lung transplantation
(70% in 1995 versus 81% in 2011) and, to amoderate
extent, after kidney transplantation [6,7].
However, despite outcome improvement, most
patients undergoing transplantation are still at high
risk for postoperative complications: immediate
death rate has been reported to reach 3% for liver
transplantation, whereas primary graft failure
remains the leading cause ofmortalitywithin 30days
following lung transplantation [5,7].Organ shortage,
extended waiting periods or advanced age often
results in patients presenting for surgery with end-
stage disease and marked co-morbidities [8]. The
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complexity of these cases usually requires multi-
disciplinary involvement at all levels, from the pre-
operative assessment until hospital discharge.
It has been suggested that some measures
specifically related to the anesthetic management
may offer organ protection and that several intra-
operative factors could play a fundamental role in
the development of postoperative complications
[9–11]. The aim of this review was to provide a
summary of recently published studies reporting
on intraoperative strategies intended to reduce post-
operative morbidity and mortality after solid organ
transplantation.
METHODS
We performed a comprehensive search for relevant
reports published in the Medline database between
January 2012 and December 2013, using the key
words ‘anesthesia’ and ‘transplantation’, without
language restriction. We considered only fully pub-
lished reports performed in adult patients (18 year
old), undergoing any type of solid organ transplan-
tation and that reported on any anesthetic strategy
aiming at reducing postoperative morbidity and
mortality. Anesthetic strategies were defined as
any intervention occurring during the intra-
operative phase, with the exception of specific
surgical strategies (procurement, graft storage or
surgical technique, for instance).
Data from animal, donor or pediatric studies
were not considered. Reports in which patients
underwent other procedures than solid organ trans-
plantation (stem cells, islets, skin, face, extremities)
were excluded. Data from studies without a com-
parison group (cross-sectional studies, surveys,
observational cohort studies) were not considered.
We also excluded trials realized in a different setting
than intraoperative and/or considering factors
occurring outside the intraoperative phase (for
instance, preoperative patient optimization or post-
operative strategies during the intensive care stay).
Trials reporting on other outcomes than post-
operative complications were not considered.
We considered reports with various levels of
evidence [randomized controlled trials (RCTs),
prospective studies, case–control studies] [12] but
included only original articles. However, in an
attempt to provide data of high quality, this article
will focus primarily on RCT.
SYNTHESIS OF RESULTS
The last online search was performed December 14,
2013: 164 articles were initially considered (Fig. 1).
Further examination led to the exclusion of nine
studies describing other outcomes than postopera-
tive complications [13–21].
Twenty studies reporting on anesthetic strat-
egies aiming at reducing postoperative morbidity
and mortality were eventually included (Table 1)
[22–41]. We retrieved 14 studies reporting on post-
operative complications in patients undergoing
liver transplantation [22–24,28,29,31–33,35–37,
39–41], five studies conducted in kidney recipients
[26,27,30,34,38] and one reporting on lung recipi-
ents [25].
BLEEDING DURING LIVER
TRANSPLANTATION
An increasing number of studies have suggested that
the administration of blood products in patients
undergoing liver transplantation was associated
with poor outcome [42–48], thus encouraging
the development of new strategies to reduce blood
products requirements. The intraoperative phase
remains crucial, as surgical technique and anes-
thetic management play a determinant role in the
prevention of bleeding.
Ongoing efforts have been made to identify pre-
dictors of perioperative bleeding. Patients under-
going liver transplantation have multiple reasons
to suffer frommajor blood loss: preoperative coagul-
opathy (impaired factor synthesis, increased con-
sumption or platelet disorders), major surgical
trauma or intraoperative adverse events (technical
difficulty, hypothermia, acidosis, hyperfibrinolysis)
are all contributing factors to perioperative hemor-
rhage [49
&&
,50]. The necessity to coordinate both
anesthetic and surgical endeavor during the oper-
ation has been underlined in a recent analysis,
suggesting that patients with an anhepatic time
of at least 60min duration were at higher risk for
perioperative bleeding and subsequent transfusion
requirements [31].
KEY POINTS
 Graft outcome may be predetermined by intraoperative
events.
 Anesthetic strategies may ensure organ protection and
improve patient outcome.
 Reducing blood products requirements, the use of
vasopressors, early extubation, perioperative glucose
control or adequate pain therapy may reduce
postoperative complications.
 Further evidence will be needed, as trial designs,
comparisons and endpoints differed widely among
studies.
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In a case–control study analyzing data from 522
patients undergoing liver transplantation, Wu et al.
[40] identified factors associated with re-laparotomy
for postoperative bleeding. Major blood loss and
subsequent administration of blood products other
than red blood cells (RBCs) [i.e. fresh frozen plasma
(FFP), platelets (PLT) or cryoprecipitate] were associ-
ated with a higher rate of re-exploration for hemo-
stasis. However, these results should be interpreted
with caution, as many confounders intervene in
retrospective studies: increased blood product
requirements and subsequent re-exploration could
be the result of inadequate primary hemostasis,
rather than the consequence of blood product
administration.
Similarly, Fayed et al. [24] investigated the
occurrence of perioperative complications in 152
patients, who were subdivided in normal versus
low preoperative platelet count (cutoff: 50109/
l). Interestingly, patients startingwith a low baseline
platelet count were not at higher risk regarding
perioperative hemorrhage or blood product require-
ment, except for FFP. Data from each group were
further analyzed according to the administration of
PLT: patients who received PLT transfusions had
higher complication rates (bleeding, duration of
mechanical ventilation and ICU stay), regardless
of their initial baseline platelet count. But here
again, caution is required: because PLT transfusion
was not prospectively assessed, these data might be
the result of confounders that were not adequately
controlled.
STRATEGIES TO REDUCE PERIOPERATIVE
BLEEDING IN LIVER RECIPIENTS
Providing a rapid bedside coagulation assessment,
thromboelastography (TEG) revolutionized the
intraoperative management of patients undergoing
major surgical procedures. The use of TEG-guided
transfusion strategies has been suggested to reduce
the administration of FFP and PLT [51,52], and TEG
is nowadays integrated in most centers’ guidelines.
20 studies reporting on anesthetic strategies susceptible to reduce postoperative morbidity and mortality
164 reports retrieved
Animal (n = 20)
Children (n = 4)
Not solid organ  (n = 22)
No comparison group (n = 17)
Other setting than intraoperative (n = 14)
29 reports initially considered
No original article (n = 49)
Donor (n = 9)
Other outcome than postoperative complications (n = 9)
Liver Kidney Heart Lung Total
RCT 6 4 0 0 10
Prospective, not RCT 1 0 0 0 1
Retrospective 7 1 0 1 9
Total 14 5 0 1 20
RCT = randomized controlled trial
FIGURE 1. Study selection and detailed search results.
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TEG values may also be used to detect intra-
operative hypercoagulability, which has been
associatedwith an increased risk of thromboembolic
complications [53,54]. Krzanicki et al. [32] investi-
gated the association of hypercoagulation with peri-
operative thrombotic events in 124 liver recipients
but were, however, unable to confirm findings
described previously.
The administration of FFP has been the center of
debate for many years and still remains a contro-
versial issue. In a recently published Cochrane
review, several methods to decrease blood loss
during liver transplantation were analyzed [55].
Most retrieved studies were at high risk of bias,
underlining the need for well designed randomized
trials to eventually reach consensus. Bindi et al. [22]
compared solvent/detergent-treated plasma to FFP
in 63 patients undergoing orthotopic liver trans-
plantation (OLT). Solvent detergent-treated plasma
has been developed by pharmaceutical industry to
reduce the transmission of transfusion-related viral
infections. Because of the filtration and inactivation
process, solvent/detergent-treated plasma has been
suggested to have a lower coagulation factors and
inhibitors content compared with FFP [49
&&
]. In the
Bindi trial, there was no difference in fluid require-
ments, RBC/PLT transfusion, need for postoperative
mechanical ventilation or renal replacement
therapy (RRT), length of ICU stay and survival at
hospital discharge. Additional trials will be needed
to confirm these results.
Vasoconstrictors play a key role in hemody-
namic management during liver transplantation.
Their specific action on splanchnic circulation
might decrease blood flow to the liver, thus reducing
bleeding and blood products requirements. Three
RCT compared the administration of vasopressors
during liver transplantation [23,28,29]. In one trial
[29], 76 patients received either phenylephrine or
dopamine/dobutamine. The estimated blood loss,
RBC and FFP transfusion were significantly lower
in the phenylephrine group. In a trial comparing
terlipressin with noradrenaline in 80 patients [23],
terlipressin was found to reduce significantly peri-
operative bleeding. However, a smaller trial failed to
confirm these findings [28].
As no clear superiority has been determined yet,
most authors recommend the use of phenylephrine
and norepinephrine for hemodynamic manage-
ment in liver transplantation [56].
ACUTE RENAL FAILURE AFTER LIVER
TRANSPLANTATION
Acute kidney injury (AKI) is a crucial issue for
patients undergoing OLT and has been reported
to occur in approximately 60% of patients post-
operatively [57]. In this analysis, RRT was required
in 8.6% of cases and mortality rates were signifi-
cantly higher in AKI-patients compared with non-
AKI patients (15.5 and 25.9% compared with 0 and
3.9%, respectively) [57].
Our search retrieved five articles: one case–
control analysis evaluated the association between
postoperative AKI and perioperative factors [36],
whereas four were RCTs comparing different vaso-
active drugs. AKI was the primary outcome in two
[23,37], whereas the other trials reported a variety
of data, including markers of the renal function
[28,29].
In the analysis of Romano et al. [36], postoper-
ative AKI was present in 56.6% of patients. Factors
associated with AKI were: Model for End-Stage Liver
Disease (MELD) score, preoperative bilirubin and
INR, the use of terlipressin during surgery, blood
products administration and a higher dose of nor-
adrenalin at ICU admission. Karapanagiotou and
coll. [58] reported a statistically significant associ-
ation between AKI and the use of vasoactive drugs.
Cirrhotic patients undergoing OLT are at risk to
develop hepatorenal syndrome: portal hypertension
leads to splanchnic vasodilatation with subsequent
intrarenal vasoconstriction and poor renal per-
fusion [59]. Vasoactive drugs have been suggested
to increase the splanchnic vascular tone, restore an
adequate renal perfusion and be effective in 40–50%
of patients with hepatorenal syndrome [60]. Their
use in the transplantation setting is, however, still
controversial. Sahmeddini and coll. [37] investi-
gated the protective effect of octreotide on renal
function in 89 patients: the octreotide group had a
significantly higher urine output, but there was no
difference in the postoperative serum creatinine
levels or need for RRT. Data regarding terlipressin
remain inconclusive: in retrospective studies, the
use of terlipressin was associated with AKI [36],
but RCT were not able to confirm this detrimental
effect [23,28].
Additional evidence will be needed to establish
recommendations for the management of AKI in
liver recipients.
PRIMARY GRAFT FAILURE, COGNITIVE
DYSFUNCTION AND OTHER
COMPLICATIONS IN LIVER RECIPIENTS
Primary graft failure remains an important cause of
mortality and one of the leading indications for
retransplantation in liver recipients [5]. A variety
of intraoperative strategies with the aim to improve
graft outcome has been investigated. Most retrieved
studies reported on surrogate markers of liver
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function but few were focusing specifically on
primary graft dysfunction (PGD). These findings
are summarized in Table 2.
Neurological complications following major
surgery are frequent, and their incidence has been
reported to reach 29.4% in patients undergoing
OLT [61]. A case-control study reported a significant
association between postoperative cognitive dys-
function, MELD scores and intraoperative blood
transfusion, but the small patient population and
the study design dampened these results [33].
Nicorandil, a vasodilator with nitrate properties,
has been reported to have cerebral protective effects
in neuronal injury models [62]. Similar findings
were reported by Xia et al. [41] in a trial comparing
nicorandil with physiological saline in 40 patients
undergoing liver transplantation: Mini-Mental-
State examination scores were significantly higher
in the nicorandil group.
The impact of early extubation after liver trans-
plantation remains still under debate. This strategy
has been suggested to improve graft outcome,
decrease pulmonary complications and reduce the
economical burden related to ICU stay [40]. In a
large retrospective analysis, 513 liver recipients were
extubated immediately after surgical procedure and
subsequently transferred to the ward without ICU
stay (fast-track strategy) [39]. Although these
patients had significantly shorter hospital stays
and increased survival rates, it remains unclear if
this benefit resulted from the fast-track strategy per
se or if it was the consequence of patient selection.
One may argue that the fast-tracked population was
significantly healthier and had less intraoperative
complications.
DELAYED GRAFT FUNCTION AFTER
KIDNEY TRANSPLANTATION
Delayed graft function (DGF), defined as the need
for RRT within 7 days of transplantation, vary from
27.3% in deceased donor kidney recipients [63] to
more than 60% with the use of expanded criteria
donor allografts [64]. In a retrospective analysis of
976 kidney recipients, DGF occurred in 21.6% of
patients and was more common in diabetic patients
with postoperative glucose greater than 160mg/dl
[34]. The authors identified several perioperative
risk factors associated with DGF; interestingly, glu-
cose level was the only intraoperative modifiable
factor associated with DGF.
PERIOPERATIVE FLUID MANAGEMENT IN
KIDNEY RECIPIENTS
Ensuring an adequate diuresis after graft anastomo-
sis is a major concern as low urine output has
been associated with lower graft survival rates
[65]. Even though a form of consensus on the risk
of AKI after hydroxyethyl starches administration
has probably been reached [66], it remains unclear
which crystalloid infusion should be used during
kidney transplantation. Kim et al. [30] compared
physiological saline with the administration of
Plasmalyte, a crystalloid solution comparable with
human plasma in terms of osmolality, pH and
electrolytes content. Although pH values were
lower in the physiological saline group, postoper-
ative outcomes did not differ between groups
(serum creatinine, urine output, need for RRT).
These results are consistent with earlier findings
on the same issue [67].
Table 2. Primary graft failure: endpoints and results
References
Study
design
No. of
patients
analyzed Comparison Endpoints Results
Fayed et al. [23] RCT 80 Terlipressin Placebo Hepatic Doppler
ultrasonography
Hepatic arterial resistive indices
and portal venous blood
flow significantly decreased
in terlipressin group
Liver tests, lactate No difference between groups
Hong et al. [28] RCT 41 Terlipressin Placebo Graft rejection No difference between groups
Hepatic artery
thrombosis
No difference between groups
Hong et al. [29] RCT 76 Phenylephrine Dopamine/
dobutamine
INR, bilirubin No difference between groups
Graft rejection, early
graft dysfunction
No difference between groups
Sahmeddini et al. [37] RCT 79 Octreotide Placebo Primary nonfunction No difference between groups
INR, international normalized ratio (prothrombin time); RCT, randomized controlled trial.
Anesthetic strategies for organ protection Hovaguimian et al.
1087-2418  2014 Wolters Kluwer Health | Lippincott Williams & Wilkins www.co-transplantation.com 127
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
PAIN CONTROL AFTER KIDNEY
TRANSPLANTATION
The benefits of regional anesthesia in kidney trans-
plantation have been widely debated in the past
10 years. Epidural anesthesia, combined with
general anesthesia or in combination with spinal
anesthesia, has been suggested to provide better
postoperative pain control [68]. Epidural anesthesia
has been reported to reduce respiratory compli-
cations in patients undergoing major abdominal
surgery [69], but this effect has not been established
in the transplantation setting yet.
Epidural anesthesia combined with general
anesthesia was compared with general anesthesia
alone in 46 kidney recipients [27]. Significant differ-
ences were reported for serum glucose, insulin,
inflammation markers (tumor necrosis factor-a,
TNF-a and interleukin-6, IL-6) and hospital length
of stay, suggesting a global protective effect with
epidural anesthesia.
Two RCT comparing the efficacy of transversus
abdominis plane (TAP) block for postoperative
pain relief reported contradictory results [26,38].
Although TAP block has been demonstrated to pro-
vide effective analgesia in various surgical settings
[70–72], its efficacy remains to be determined in
patients undergoing kidney transplantation.
PRIMARY GRAFT DYSFUNCTION IN LUNG
RECIPIENTS
Felten et al. [25] reported on a variety of intra-
operative factors associated with the occurrence of
PGD. In their analysis, 122 recipients were divided
into three groups, according to their grade of
PGD (grade I: PaO2/FiO2>300mmHg; grade II:
PaO2/FiO2¼200–300mmHg; grade III: PaO2/FiO2<
200mmHg). Intraoperative RBC administration was
associated with a significant higher risk to develop
Grade III PGD. Ina similar study [73
&&
], intraoperative
transfusion of RBC and FFP was associated with a
significant increase inmortality after lung transplan-
tation in 134 patients.
FUTURE PERSPECTIVES
To date, there is still no consensus on the best drug
to achieve anesthesia maintenance during solid
organ transplantation [9,56]. Volatile anesthetics
have been suggested to provide protection against
ischemia–reperfusion injury in a variety of surgical
settings [74–76]. Their effect in the transplantation
setting is the primary focus of several trials that are
still in progress (NCT00913276; NCT01248871;
NCT01936545; NCT00337051; NCT01870011;
NCT02009280; NCT01132157 in: clinicaltrials.gov).
The use of nitric oxide (NO) donor agents has been
suggested to reduce ischemia–reperfusion injury in
liver and lung recipients [77], but few studies have
reported high-quality data. The administration of
NO is being currently investigated in three trials
(NCT00582010; NCT01172691; NCT00948194 in:
clinicaltrials.gov).
CONCLUSION
Considerable efforts have been made to identify
intraoperative factors associated with postoperative
complications. Our search retrieved several promis-
ing strategies to ensure organ protection and
improve patient outcome such as decreasing blood
products requirements, adequate blood glucose con-
trol or the use of regional anesthesia if possible.
However, results were difficult to compare, as study
designs, comparisons and endpoints differed widely
among reports. The debate on intraoperative organ
protection seems, therefore, to have just started and
further evidence will be needed before drawing
firm conclusions.
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